Moody’s Investors Service (“Moody’s”) has upgraded the corporate credit rating of Fresenius Medical Care, the world’s largest provider of dialysis products and services, from Ba1 to Baa3 with a stable outlook.

In addition, Moody's has upgraded all senior unsecured ratings from Ba2 to Baa3 and confirmed all senior secured ratings of Fresenius Medical Care at Baa3.

The upgrades reflect Moody’s view about Fresenius Medical Care’s strong track record of profitable growth, the company’s defensive business profile, as well as its ability to quickly delever after debt-financed acquisitions.

Moody’s further recognizes the solid growth outlook for Fresenius Medical Care driven by continued patient growth and prospects for international expansion.

The growth targets of the company’s 2020 strategy reflect the realization of these opportunities.

Fresenius Medical Care is now rated investment grade by Standard & Poor’s, Moody’s and Fitch.